FAQ on Roth Capital Partners' Role in CapsoVision's $27.5 Million IPO

What was Roth Capital Partners’ role in CapsoVision’s IPO?

Roth Capital Partners acted as joint book-running manager for CapsoVision’s initial public offering, facilitating the sale of 5,500,000 shares at $5.00 per share.

How much did CapsoVision raise in its IPO?

CapsoVision raised approximately $27.5 million in gross proceeds before deductions from its IPO.

When did CapsoVision’s shares start trading on the Nasdaq Capital Market?

CapsoVision’s shares began trading on the Nasdaq Capital Market on July 2, 2025, under the ticker symbol ‘CV’.

What is CapsoVision’s focus area?

CapsoVision is a commercial-stage medical technology company focused on AI-powered capsule endoscopy solutions.

Did the underwriters have an option to purchase additional shares?

Yes, the company granted underwriters a 30-day option to purchase up to an additional 825,000 shares at the IPO price.

Where can I find more information about Roth Capital Partners?

For more information on Roth Capital Partners, please visit their website at www.roth.com.

What services does Roth Capital Partners offer?

Roth Capital Partners offers a full service platform including capital raising, equity research, macroeconomics, sales and trading, technical insights, derivatives strategies, M&A advisory, and corporate access.

Where is Roth Capital Partners headquartered?

Roth Capital Partners is headquartered in Newport Beach, California, and maintains offices throughout the U.S.

What is InvestorWire?

InvestorWire is a specialized communications platform focusing on advanced wire-grade press release syndication for private and public companies and the investment community, part of the Dynamic Brand Portfolio @ IBN.

Where can I view the announcement of CapsoVision’s IPO?

The announcement of CapsoVision’s IPO can be viewed at https://ibn.fm/D3xFn.